drugset / Trial / NCT00125385
Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study is designed to investigate whether GC1008, an antibody that neutralizes TGFb, is safe in treating patients with idiopathic pulmonary fibrosis. The highest dose without excessive side effects will be identified. Tests will determine how long GC1008 is in the body and how it is excreted.
Timeline
- Start
- 2005-07
- Primary completion
- 2008-09
- Completion
- 2008-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fresolimumab | Protein / enzyme biologic | 0.3 mg/kg | Intravenous |
| Subject | Fresolimumab | Protein / enzyme biologic | 1 mg/kg | Intravenous |
| Subject | Fresolimumab | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Subject | Fresolimumab | Protein / enzyme biologic | 4 mg/kg | Intravenous |
| Subject | Fresolimumab | Protein / enzyme biologic | 8 mg/kg | Intravenous |